Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
|Videos|July 17, 2021
Dr. Gupta discusses avelumab first-line maintenance treatment for advanced urothelial carcinoma
Author(s)Urology Times staff
“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.
Advertisement
In this video, Shilpa Gupta, MD, discusses key findings from the study, "Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance,” which was presented at the 2021 ASCO annual meeting. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Advertisement
Related to this article
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Novel RIPTAC molecule shows promising activity in heavily pretreated mCRPC
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
LUGPA 2026: Midterms, AI, and ancillary services take center stage
4
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
5